Literature DB >> 34901585

Breast cancer immunotherapy: current biomarkers and the potential of in vitro assays.

Melissa C Skala1,2, Jose M Ayuso3, Mark E Burkard4,5,6, Dustin A Deming4,5,6.   

Abstract

Breakthroughs in metastatic breast cancer care require new model systems that can identify the unique features and vulnerabilities of each cancer. Primary tumor cultures are proposed to efficiently screen multiple treatment options in a patient-specific strategy to maximize therapeutic benefit, minimize toxicity, and enable mechanistic insights that inspire future biomarkers for patient selection. To realize the potential of patient-specific cultures, new tools are needed to capture cell-by-cell variability in behavior and dynamic response to treatments in living 3D specimens. Potential bioengineering tools that can achieve this include optical microscopy to image single-cell dynamics and microphysiological in vitro systems to evaluate cell-cell interactions and immunotherapies.

Entities:  

Year:  2021        PMID: 34901585      PMCID: PMC8654237          DOI: 10.1016/j.cobme.2021.100348

Source DB:  PubMed          Journal:  Curr Opin Biomed Eng        ISSN: 2468-4511


  47 in total

1.  Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations.

Authors:  Tyler M Foley; Susan N Payne; Cheri A Pasch; Alex E Yueh; Dana R Van De Hey; Demetra P Korkos; Linda Clipson; Molly E Maher; Kristina A Matkowskyj; Michael A Newton; Dustin A Deming
Journal:  Mol Cancer Res       Date:  2017-02-09       Impact factor: 5.852

Review 2.  Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations.

Authors:  Jesse J Salk; Michael W Schmitt; Lawrence A Loeb
Journal:  Nat Rev Genet       Date:  2018-03-26       Impact factor: 53.242

3.  Tumor heterogeneity confounds and illuminates: assessing the implications.

Authors:  Maria Kleppe; Ross L Levine
Journal:  Nat Med       Date:  2014-04       Impact factor: 53.440

4.  Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.

Authors:  Javier Cortes; David W Cescon; Hope S Rugo; Zbigniew Nowecki; Seock-Ah Im; Mastura Md Yusof; Carlos Gallardo; Oleg Lipatov; Carlos H Barrios; Esther Holgado; Hiroji Iwata; Norikazu Masuda; Marco Torregroza Otero; Erhan Gokmen; Sherene Loi; Zifang Guo; Jing Zhao; Gursel Aktan; Vassiliki Karantza; Peter Schmid
Journal:  Lancet       Date:  2020-12-05       Impact factor: 79.321

5.  Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.

Authors:  Rita Nanda; Laura Q M Chow; E Claire Dees; Raanan Berger; Shilpa Gupta; Ravit Geva; Lajos Pusztai; Kumudu Pathiraja; Gursel Aktan; Jonathan D Cheng; Vassiliki Karantza; Laurence Buisseret
Journal:  J Clin Oncol       Date:  2016-05-02       Impact factor: 44.544

6.  Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer.

Authors:  Hauke Stamm; Leticia Oliveira-Ferrer; Eva-Maria Grossjohann; Jana Muschhammer; Vanessa Thaden; Franziska Brauneck; Roman Kischel; Volkmar Müller; Carsten Bokemeyer; Walter Fiedler; Jasmin Wellbrock
Journal:  Oncoimmunology       Date:  2019-10-12       Impact factor: 8.110

Review 7.  Understanding the Warburg effect: the metabolic requirements of cell proliferation.

Authors:  Matthew G Vander Heiden; Lewis C Cantley; Craig B Thompson
Journal:  Science       Date:  2009-05-22       Impact factor: 47.728

Review 8.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

9.  Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer.

Authors:  Woosung Chung; Hye Hyeon Eum; Hae-Ock Lee; Kyung-Min Lee; Han-Byoel Lee; Kyu-Tae Kim; Han Suk Ryu; Sangmin Kim; Jeong Eon Lee; Yeon Hee Park; Zhengyan Kan; Wonshik Han; Woong-Yang Park
Journal:  Nat Commun       Date:  2017-05-05       Impact factor: 14.919

10.  Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment.

Authors:  Joe T Sharick; Christine M Walsh; Carley M Sprackling; Cheri A Pasch; Dan L Pham; Karla Esbona; Alka Choudhary; Rebeca Garcia-Valera; Mark E Burkard; Stephanie M McGregor; Kristina A Matkowskyj; Alexander A Parikh; Ingrid M Meszoely; Mark C Kelley; Susan Tsai; Dustin A Deming; Melissa C Skala
Journal:  Front Oncol       Date:  2020-05-15       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.